TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04377256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation: Tooth extration and immediat bone grafting in the socket
Description: Following the tooth extraction, the socket is filled with a mixture of xenogenic bone and hyaluronic acid and sealed with an epithelio-connective arrested from the maxillary palate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation: Tooth extration and immediat bone grafting in the socket
Description: Following the tooth extraction, the socket is filled with a mixture of xenogenic bone and hyaluronic acid and sealed with an epithelio-connective arrested from the maxillary palate
Study: NCT04198337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Full Thickness Resection
Description: Endoscopic full thickness resection achieved by resecting the submucosal tumor using retraction techniques and submucosal dissection, followed by closure
Study: NCT02735642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Randomization 1 - Referral
Description: Participants will be randomized to receive standard referral to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Randomization 1 - Referral and SMS
Description: Participants will be randomized to receive referral plus SMS to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
Study: NCT03516981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: 200 mg or 800 mg favezelimab solution for IV infusion administered Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: 200 mg or 800 mg favezelimab solution for IV infusion administered Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: 200 mg or 800 mg favezelimab solution for IV infusion administered Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: 200 mg or 800 mg favezelimab solution for IV infusion administered Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg lenvatinib capsules administered orally once daily
Study: NCT00355667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemide
Description: Patients with chronic heart failure receive furosemide and other standard treatment/

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azosemide
Description: Patients with chronic heart failure receive azosemide and other standard treatment.
Study: NCT01403987

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Residency Program Teaching
Description: The residency program provides education surrounding the management of ascites to all house-staff in the training program. This consists of lectures, case-based or bedside discussions, and board review. All arms will receive the standard teaching provided by the residency program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Residency Program Teaching
Description: The residency program provides education surrounding the management of ascites to all house-staff in the training program. This consists of lectures, case-based or bedside discussions, and board review. All arms will receive the standard teaching provided by the residency program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Residency Program Teaching
Description: The residency program provides education surrounding the management of ascites to all house-staff in the training program. This consists of lectures, case-based or bedside discussions, and board review. All arms will receive the standard teaching provided by the residency program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lecture
Description: During resident rotations on inpatient wards there are typically several dedicated, one-hour discussions facilitated by the team's supervising attending, addressing a variety of internal medicine topics. In place of or in addition to one of these discussions, a gastroenterology fellow will meet with the team for one hour to discuss a standardized case of a patient with ascites and the management issues. At this time they will review the consensus guidelines for management, and be provided with a pocket card with key points.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lecture
Description: During resident rotations on inpatient wards there are typically several dedicated, one-hour discussions facilitated by the team's supervising attending, addressing a variety of internal medicine topics. In place of or in addition to one of these discussions, a gastroenterology fellow will meet with the team for one hour to discuss a standardized case of a patient with ascites and the management issues. At this time they will review the consensus guidelines for management, and be provided with a pocket card with key points.
Study: NCT03516981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg lenvatinib capsules administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg lenvatinib capsules administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg lenvatinib capsules administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quavonlimab
Description: Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quavonlimab
Description: Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
Study: NCT01403987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pocket Card Reference
Description: A 4x6 inch laminated card will be administered to both intervention arms at the beginning of the study. The card will contain a brief summary of AASLD guidelines, indications for and contraindications to paracentesis, and key studies to order for fluid analysis. The organization of residency rotations is such that members of one randomization group do not typically work with members of other groups, however in the event that there is crossover, they will be free to share information as they see fit in order to optimize patient care.
Study: NCT03516981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quavonlimab
Description: Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
Study: NCT02735642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Randomization 2 - SMS
Description: Those that have not linked to care after the first randomization, will be re-randomized to receive an SMS message. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Randomization 2 - Incentive
Description: Those that have not linked to care after the first randomization, will be re-randomized to receive a one-time economic incentive. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: High Risk Negative Cohort (N=185)
Description: A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185). They will receive an SMS health promotion message with survey at 6 and 12 months. At 12 months, they will be re-tested for HIV and an exit interview completed.

Intervention type: OTHER
Group type: OTHER
Intervention: All participants. Approximately (N=1200)
Description: HIV testing approaches that females can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).~All participants will receive a behavioral CAPI survey at baseline visit, an SMS HIV test experience satisfaction survey, and for those who choose the self-testing option, a staff-administered questionnaire.
Study: NCT02075684

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal Biopsy
Study: NCT04680208

Intervention type: PROCEDURE
Intervention: Surgical procedure under anesthesia
Description: Different varieties of surgical procedures done under anesthesia

Intervention type: PROCEDURE
Intervention: Surgical procedure under anesthesia
Description: Different varieties of surgical procedures done under anesthesia
Study: NCT03871504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submaximal isometric exercise
Description: The exercise is a submaximal isometric contraction
Study: NCT02039206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep TMS
Description: 1Hz Stimulation
Study: NCT01403987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pocket Card Reference
Description: A 4x6 inch laminated card will be administered to both intervention arms at the beginning of the study. The card will contain a brief summary of AASLD guidelines, indications for and contraindications to paracentesis, and key studies to order for fluid analysis. The organization of residency rotations is such that members of one randomization group do not typically work with members of other groups, however in the event that there is crossover, they will be free to share information as they see fit in order to optimize patient care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pager
Description: The intensive education arm will be given a pager number at their initial meeting that they can use to call for personal assistance with performing paracentesis. Since a paracentesis is frequently referred to by housestaff as a tap, the pager number will correlate with the letters, TAPS, or #8277. The goal of the pager is to provide supervision and individual teaching so that the care provider can become proficient in the procedure.
Study: NCT03522428

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin b12
Description: Vitamin B12 has been added to the experimental group of pregnant women, at a dose of 5 μg / 100 days
Study: NCT03939637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Starting dose for eltrombopag will be based on manufacturer recommendations, and drug will be titrated to effect per guidelines.~* Children 1 to 5 years: Initial: 25 mg once daily~* Children ≥6 years and Adolescents: Initial: 50 mg once daily (25 mg once daily for patients of East-Asian ethnicity \[e.g., Chinese, Japanese, Korean, Taiwanese\])~Dose should be titrated based on platelet response. Maximum dose: 75 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Prednisone/Prednisolone 4mg/kg/day (Max 120 mg/day) x 4 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)
Study: NCT01345903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo robotic-assisted surgery
Study: NCT01918020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go Wild with Fruits and Veggies!
Description: Fruits and Vegetables

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Go Wild with Fruits and Veggies! delayed
Description: Go Wild with Fruits and Veggies! delayed
Study: NCT03160573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClōSYS® Unflavored Rinse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClōSYS® Flavored Rinse

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Flavored Oral Rinse
Description: Flavor-matched placebo rinse

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Unflavored Oral Rinse
Description: Unflavored-matched placebo rinse
Study: NCT00488293

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Store and forward teledermatology
Description: Standard electronic consult, standardized history, and image set
Study: NCT03939637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rho(D) Immune Globulin
Description: Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)
Study: NCT03906955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Efficacy for Lifestyle PA
Description: The intervention group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for engaging in lifestyle physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Efficacy for Work-life Balance
Description: The time-matched control group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for work-life balance.
Study: NCT01276535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia MLS + Erchonia THL
Description: The Erchonia® MLS is administered weekly for 6 continuous weeks at the test site by the study investigator.~The Erchonia THL is administered twice daily for 6 continuous weeks (42 days) at home by the subject.~Administration of the MLS and the THL occur simultaneously over the 6-week administration phase.~The intent is to evaluate the effectiveness of Erchonia MLS \& Erchonia THL when administered together, and not to compare Erchonia MLS vs. Erchonia THL
Study: NCT04021368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVU120(SEL120)
Description: RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.
Study: NCT02324907

Intervention type: DEVICE
Intervention: Procedure/Surgery
Description: Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
Study: NCT02416479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SystemCHANGE
Description: SystemCHANGE self-management supports patient-designed, interventionist-guided, small experiments using Deming's Plan-Do-Check-Act cycle26 to: (1) assess individual systems (including important others who shape medication taking), how they influence medication taking and their proposals for improving medication adherence, (2) implement the proposed individual systems' solutions to improve adherence, (3) track adherence data, and (4) evaluate adherence data.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient-education attention control
Description: The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
Study: NCT03752372

Intervention type: PROCEDURE
Intervention: hematopoietic stem cell transplantation
Description: 1. Reduced intensity conditioning(RIC) chemotherapy regimen before transplantation~2. All patients were cared for in single rooms ventilated with a highly effective particulate air filtration system. All patients received intravenous immunoglobulin and antimicrobial prophylaxis, which included antiviral, antifungal, and Pneumocystis jirovecii prophylaxis with ganciclovir and micafungin, as per routine clinical practice before transplantation.~3. Umbilical cord blood transplantation
Study: NCT04127110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).
Study: NCT03345810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Induction: (1125 mg) cycle Q3W Maintenance: (1500 mg) cycle Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Induction: (1125 mg) cycle Q3W Maintenance: (1500 mg) cycle Q4W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: (30 mg/m2 D1 + D8 as infusion) cycle Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: (30 mg/m2 D1 + D8 as infusion) cycle Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: (1000 mg/m2 D1 + D8 as infusion) cycle Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: (1000 mg/m2 D1 + D8 as infusion) cycle Q3W
Study: NCT05745532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: β-globin restored autologous hematopoietic stem cells
Description: β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
Study: NCT03345810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: (100 mg/m2 intravenous infusion over 30 minutes on D1, D8) cycle Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: (100 mg/m2 intravenous infusion over 30 minutes on D1, D8) cycle Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: (AUC = 5 mg•min/mL on Day 1) cycle Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: (AUC = 5 mg•min/mL on Day 1) cycle Q3W
Study: NCT00382863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartNet Ventricular Support System
Description: The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical/Device Therapy
Description: Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
Study: NCT02016885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrrolate, 1.0%
Description: glycopyrrolate Topical Wipes, 1.0%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrrolate, 2.0%
Description: glycopyrrolate Topical Wipes, 2.0%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrrolate, 3.0%
Description: glycopyrrolate Topical Wipes, 3.0%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrrolate, 4.0%
Description: glycopyrrolate Topical Wipes, 4.0%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Topical Wipes
Study: NCT04469946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oticon OpenSound Navigator speech enhancement algorithm
Description: OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
Study: NCT02474511

Intervention type: OTHER
Intervention: general anesthesia and local anesthesia
Description: the patient received generalanesthesia and local anesthesia randomly

Intervention type: OTHER
Intervention: general anesthesia and local anesthesia
Description: the patient received generalanesthesia and local anesthesia randomly
Study: NCT03950401

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl
Description: subcuticular Monocryl wound closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nylon
Description: wound closure using nylon suture on the skin
Study: NCT04171804

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Participants will receive a total of 10 stimulation sessions on 5 consecutive days (twice a day with 3-4 hours interval). During each session, 2 milliAmpers (mA) of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Participants will receive a total of 10 stimulation sessions on 5 consecutive days (twice a day with 3-4 hours interval). During each session, 2 milliAmpers (mA) of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
Study: NCT01853163

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gadolinium analysis in bone and tissue samples
Description: Gadolinium analysis in bone and tissue samples from patients undergoing an orthopaedic surgical procedure who had received GBCAs in the past.